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Background: 
 Despite recent advances in therapeutics, lung squamous cell carcinoma (LSCC) remains 
a challenging disease to treat. The advent of immune-checkpoint inhibitors along with several 
active target agents such as antiangiogenic agents has altered LSCC treatment to some extent, 
but treatment options remain limited. To date, very few druggable mutations and active predict
ive biomarkers have been identified; thus, no LSCC-specific target therapy has yet been establ
ished. The development of precision medicine with truly active target drugs is eagerly awaited.
  We previously found that Syntaxin Binding Protein 4 (STXBP4) plays a crucial role in  
lesion growth and, therefore, clinical outcomes in LSCC patients through regulation of tumor  
protein p63 (TP63) ubiquitination. ΔNp63 is an isoform of TP63, a member of the TP53 family, 
and its expression is widely used as a highly specific diagnostic marker for LSCC. STXBP4 bind
s to ΔNp63 and suppresses the anaphase-promoting complex/cyclosome (APC/C) complex-mediated  
proteolysis of ΔNp63, and drives the oncogenic potential of ΔNp63α. STXBP4 may be a useful 
therapeutic target and/or marker for patients with LSCC. 
 
Methods:  
To clarify the impact of STXBP4 and TP63 for LSCC therapeutics, we assessed relevance 
of these proteins to outcome of 144 LSCC patients at Gunma University Hospital from April 2001
 to December 2014.  
In addition, we examined whether its action pathway is distinct from those of currently used  
drugs in in vitro experiments including RNA-seq analysis through comparison with the other    
putative exploratory targets and/or markers including VEGFR2 (vascular endothelial growth     
factor receptor 2), TUBB3 (tubulin beta 3), and PD-L1 (programmed cell death 1 ligand 1),     
along with p53 (tumor protein p53), ΔNp63 and STMN1 (stathmin 1). 
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Results:  
Kaplan– Meier analysis revealed that, along with vascular endothelial growth factor recept
or 2 (VEGFR2), STXBP4 expression signified a worse prognosis in LSCC patients, both in terms of    
overall survival (OS, p = 0.002) and disease-free survival (DFS, p = 0.041). These prognostic      
impacts of STXBP4 were confirmed in univariate Cox regression analysis, but not in the multivariate
analysis. Whereas, TP63 (ΔNp63) closely related to OS (p = 0.013), and shown to be an independent 
prognostic factor for poor OS in the multivariate analysis (p = 0.0324). The action pathway of     
STXBP4 on suppression of TP63 (ΔNp63) was unique: Ingenuity pathway analysis using the knowledge  
database and our RNAseq analysis in human LSCC cell lines indicated that 35 pathways were activated
or inactivated in association with STXBP4, but the action pathway of STXBP4 was distinct from those
of other current drug targets: STXBP4, TP63 and KDR (VEGFR2 gene) formed a cluster independent from
other target genes of tumor protein p53 (TP53), tubulin beta 3 (TUBB3), stathmin 1 (STMN1) and     
cluster of differentiation 274 (CD274: programmed cell death 1 ligand 1, PD-L1). STXBP4 itself     
appeared not to be a potent predictive marker of individual drug response, but we found that TP63, 
main action target of STXBP4, might be involved in drug resistance mechanisms of LSCC. 
 
Conclusion:  
STXBP4 and the action target, TP63, could afford a key to the development of precision med
icine for LSCC patients. 
 
